Absolute Bioavailability of Lu AE58054 in Healthy Subjects

Interventional, Open-label Study Investigating the Absolute Bioavailability of Lu AE58054 After Multiple Oral Dosing and a Single Radio-labelled Intravenous Micro-dose as Well as the Contribution of Cytochrome P450 2D6 to the Exposure of Lu AE58054 in Healthy Subjects

To determine the absolute bioavailability of the Lu AE58054 tablet formulation at steady state

Inclusion Criteria:

• Healthy men and women aged between 21-55 years (inclusive) and with an BMI in the range 18.5 to 32 kg/m2 (minimum weight 60 kg for men and 55 kg for women).
• The subjects CYP2D6 genotype must be determined before inclusion into the study.
• Women must not be pregnant or lactating.

Exclusion Criteria:

• The subject is, in the opinion of the investigator, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.